Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivastigmine - Novartis

Drug Profile

Rivastigmine - Novartis

Alternative Names: ENA 713; ENA 713D; Exelon; Exelon Patch; Exelon TDS; ONO-2540; Prometax; Rivastach Patch; Rivastigmine transdermal system; SDZ 212713; SDZ ENA 713

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Ono Pharmaceutical
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Dementia
  • No development reported Delirium

Most Recent Events

  • 01 Sep 2023 Almirall SA acquires exclusive rights to Rivastigmine in Spain from Novartis
  • 26 May 2021 Rivastigmine licensed to Knight Therapeutics in Canada and Latin America
  • 08 Apr 2021 No development reported - Phase-III for Delirium (In the elderly) in France (Transdermal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top